Incannex Healthcare Inc. (IXHL) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Incannex Healthcare Inc. (IXHL) closed at USD 2.86 on 2026-10-14, a change of -73.4 % over the past year, with a market capitalization of USD 36.13M.

Incannex Healthcare Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Incannex Healthcare Inc. key figures

Previous close

USD 2.86 (2026-10-14)

1-year change

-73.4 %

Market cap

USD 36.13M

Enterprise value

USD -31.49M

P/E ratio (trailing)

-1.75

P/E ratio (forward)

-1.69

EPS (trailing)

-1.65

EPS (forward)

-1.71

PEG ratio

n/a

Price to book

0.54

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.74

Employees

12

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Incannex Healthcare Inc.

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. The company is headquartered in Melbourne, Australia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Incannex Healthcare Inc. and compare it with other stocks.